Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) but lowers the price target from $17 to $16.
August 09, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Recursion Pharmaceuticals but lowers the price target from $17 to $16.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100